ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Efficacy Comparison of Toripalimab versus Pembrolizumab in Neoadjuvant Treatment of Breast Cancer: Impact of Chemotherapy Regimen and Sequence on Pathologic Complete Response
Provisionally accepted
- 1Xijing Hospital Thyroid, Breast and Vascular Surgery Department, Xi'an, China
- 2Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
- 3Air Force Medical University, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This real-world study aimed to compare the efficacy and safety of the domestically developed PD-1 inhibitor toripalimab with pembrolizumab in the neoadjuvant treatment of breast cancer, and to further investigate the impact of treatment cycles, platinum-based chemotherapy, and chemotherapy sequencing on pathologic complete response (pCR). Methods: This retrospective study included 114 breast cancer patients who received neoadjuvant therapy with either toripalimab or pembrolizumab at the First Affiliated Hospital of Air Force Medical University between January 2021 and January 2025. Participants were stratified into groups based on: (1) immunotherapy cycles (completed 8 cycles vs. incomplete); (2) chemotherapy regimen (platinum vs. non-platinum); (3) chemotherapy sequence (EC-T, EC-TCb, T-EC, TCb-EC, or other); and (4) PD-1 inhibitor type (toripalimab vs. pembrolizumab). The primary endpoint was total pCR (tpCR; ypT0/is ypN0). Secondary endpoints included breast pCR (bpCR) and residual cancer burden (RCB). Statistical analyses incorporated Chi-square tests and Fisher's exact tests for group comparisons. Baseline characteristics were compared across groups to assess the potential for confounding. Results: No significant differences were observed in tpCR (56.7% vs. 46.8%; P = 0.297) or RCB-0 rates (56.7% vs. 44.7%; P = 0.524) between patients completing versus not completing 8 immunotherapy cycles. The tpCR rate did not differ significantly between platinum-based and non-platinum-based regimens (53.6% vs. 51.7%, P=0.843). Chemotherapy sequence significantly affected efficacy: the TCb-EC group achieved the highest tpCR rate (79.2%), significantly outperforming EC-T (56.4%) and other regimens (27.3%). Toripalimab and pembrolizumab showed no significant difference in tpCR rate (56.8% vs. 50.0%, P=0.777) or RCB-0 rate (56.8% vs. 48.6%, P=0.903). Conclusion: Toripalimab demonstrated non-inferior efficacy compared to pembrolizumab in the neoadjuvant treatment of breast cancer. Chemotherapy sequence—particularly the TCb-EC regimen— significantly predicted pCR, while immunotherapy cycle number and platinum use did not influence pathologic outcomes. These real-world findings support toripalimab's clinical use and underscore the importance of optimizing chemoimmunotherapy sequencing.
Keywords: breast cancer, Neoadjuvant Therapy, immune checkpoint inhibitors, Toripalimab, Pembrolizumab, Pathologic complete response, Real-world study
Received: 03 Oct 2025; Accepted: 29 Nov 2025.
Copyright: © 2025 Zhang, Zhangbo, Chen, Zhang, Liu, Wang and Ling. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhe Wang
Rui Ling
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.